CAL-120Homo sapiens (Human)Cancer cell line

Also known as: CAL120, CAL 120

🤖 AI SummaryBased on 10 publications

Quick Overview

CAL-120 is a human cancer cell line used in research for studying cancer biology and drug development.

Detailed Summary

CAL-120 is a human cancer cell line derived from an unspecified tissue and disease. It is utilized in various research applications including the study of cancer genetics, drug sensitivity, and molecular pathways. The cell line is part of large-scale studies that analyze genomic and transcriptomic data to identify potential therapeutic targets. Research involving CAL-120 contributes to understanding the complexities of cancer biology and the development of personalized treatment strategies.

Research Applications

Cancer geneticsDrug sensitivityMolecular pathwaysPersonalized treatment strategies

Key Characteristics

Genomic and transcriptomic analysisCancer biology researchTherapeutic target identification
Generated on 6/16/2025

Basic Information

Database IDCVCL_1104
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age43
Age CategoryAdult
SexFemale
Subtype Featuresbasal_B TNBC

Disease Information

DiseaseBreast carcinoma
LineageBreast
SubtypeInvasive Breast Carcinoma
OncoTree CodeBRCA

DepMap Information

Source TypeDSMZ
Source IDACH-000212_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.672+2T>GHomozygousSplice donor mutationUnknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
12
D16S539
12
D18S51
12
D19S433
13,14
D21S11
30
D2S1338
20,26
D3S1358
18
D5S818
13
D7S820
12
D8S1179
12,13
FGA
21
Penta D
13
Penta E
11
TH01
6
TPOX
8,9
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Improving the metabolic fidelity of cancer models with a physiological cell culture medium.

Kalna G., Nixon C., Blyth K., Gottlieb E., Tardito S.

Sci. Adv. 5:eaau7314.1-eaau7314.14(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).